Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Filtros aplicados
Base de dados
Intervalo de ano de publicação
1.
Int. microbiol ; 26(2): 165-177, May. 2023. graf
Artigo em Inglês | IBECS | ID: ibc-220213

RESUMO

Emergence of Candida auris, a multidrug-resistant yeast, demonstrates the urgent need for novel antifungal agents. Human antimicrobial peptides (AMPs) are naturally occurring molecules with wide spectrum antimicrobial activity, particularly against a variety of fungi. Therefore, this study examined the antifungal activity of seven different human AMPs against C. auris following the CLSI guidelines. The antifungal activity was further assessed using time kill curve and cell viability assays. For combination interaction, effectiveness of these peptides with three antifungals, fluconazole, amphotericin B, and caspofungin was done following standard protocols. To elucidate the antifungal mechanism, the effects of peptides on membrane permeability were investigated using propidium iodide staining method and confocal imaging. Antifungal susceptibility results showed that all the examined peptides possessed fungicidal effect against C. auris at different levels, with human β-defensin-3 being the most potent antifungal with MIC values ranging from 3.125 to 12.5 µg/ml. Time kill curves further confirmed the killing effect of all the tested peptides. Viability assay showed a significant decrease in the percentage of viable cells exposed to different inhibitory and fungicidal concentrations of each peptide (p < 0.01). Furthermore, peptides showed mostly synergistic interaction when combined with conventional antifungal drugs, with caspofungin showing 100% synergy when combined with different AMPs. As antifungal mechanism, peptides disrupted the membrane permeability at concentrations that correlated with the inhibition of growth. Overall, the findings of this study point towards the application of the tested peptides as a monotherapy or as a combination therapy with antifungal drugs to treat multidrug-resistant C. auris infections.(AU)


Assuntos
Humanos , Peptídeos Catiônicos Antimicrobianos , Candida , Permeabilidade da Membrana Celular , Antifúngicos , Pesquisa
2.
J. physiol. biochem ; 78(2): 335–342, May. 2022. graf
Artigo em Inglês | IBECS | ID: ibc-215962

RESUMO

Human cathelicidin refers to the cationic antimicrobial peptide hCAP18/LL-37. LL-37 is formed by cleavage of the propeptide hCAP18 coded by the CAMP gene. The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)D), has been shown to induce the CAMP gene expression through promoter activation. We previously failed to demonstrate in a clinical trial that supplementation of 25-hydroxyvitamin D (25(OH)D) improves LL-37 serum levels. The aim of this work was to evaluate the impact of 25(OH)D supplementation on intracellular expression of CAMP and secretion of LL-37 in an ex vivo model using the peripheral blood mononuclear cells (PBMC). PBMC collected from healthy donors and incubated with different concentrations of 25(OH)D (0 ng/ml: control (D0); 25 ng/ml: deficient (D25); 75 ng/ml: physiological (D75); 125 ng/ml: supraphysiological (D125)) were stimulated or not with lipopolysaccharide (LPS, 100 ng/ml) or synthetic double-stranded RNA Poly (I: C) (PIC, 10 µg/ml). The intracellular expressions of the CAMP gene and the hCAP18 peptide were measured respectively after 24-h and 48-h incubation periods. The concentration of LL-37 was determined in the culture medium after 48-h incubation. 25(OH)D significantly induced CAMP gene expression at 24 h with a maximum effect at a dose of D125 in either unstimulated (tenfold expression) or stimulated (LPS: 100-fold expression; PIC: 15-fold expression) conditions. Intracellular hCAP18 peptide was overexpressed at 48 h under unstimulated (1.5-fold, D125) and stimulated conditions, LPS (twofold, D125) and PIC (2.5-fold, D125). The secretion of LL-37 in the culture medium was significantly induced by 25(OH)D only in both stimulated (LPS and PIC) conditions in a dose-dependent manner. (AU)


Assuntos
Humanos , Leucócitos Mononucleares , Lipopolissacarídeos/farmacologia , França , Vitamina D , Peptídeos Catiônicos Antimicrobianos , Calcifediol , Catelicidinas
4.
Int. microbiol ; 20(1): 43-53, mar. 2017. tab, graf
Artigo em Inglês | IBECS | ID: ibc-163955

RESUMO

We studied the prospect of synergy between the antimicrobial peptide p138c and non-peptide antibiotics for increasing the potency and bacterial killing kinetics of these agents. The production of p138c was maximized in the late exponential growth phase of Bacillus subtilis CSB138. Purification of p138c resulted in a total of 4800 arbitrary units (AU) with 19.15-fold and 3.2% recovery. Peptide p138c was thermo-tolerant up to 50 °C and stable at pH 5.8 to 11. The biochemical nature of p138c was determined by a bioassay, similar to tricine-SDS-PAGE, indicating inhibition at 3 kDa. The amino acid sequence of p138c was Gly-Leu-Glu-Glu-Thr-Val-Tyr-Ile-Tyr-Gly-Ala-Asn-Met-X-Ser. Potency and killing kinetics against vancomycin-resistant Staphylococcus aureus improved considerably when p138c was synergized with oxacillin, ampicillin, and penicillin G. The minimal inhibitory concentration (MIC) of p138c showed a 4-, 8-, and 16-fold improvement when p138c was combined with oxacillin, ampicillin, and penicillin G, respectively. The fractional inhibitory concentration index for the combination of p138c and oxacillin, ampicillin, and penicillin G was 0.3125, 0.25, and 0.09, respectively. Synergy with non-peptide antibiotics resulted in enhanced killing kinetics of p138c. Hence, the synergy between antimicrobial peptide and non-peptide antibiotics may enhance the potency and bacterial killing kinetics, providing more potent and rapidly acting agents for therapeutic use (AU)


No disponible


Assuntos
Peptídeos Catiônicos Antimicrobianos/isolamento & purificação , Bacillus subtilis/imunologia , Sinergismo Farmacológico , Farmacocinética , Crescimento Bacteriano/análise , Testes de Sensibilidade Microbiana
5.
Rev. toxicol ; 33(1): 31-38, 2016. tab
Artigo em Espanhol | IBECS | ID: ibc-153971

RESUMO

Artemia franciscana "camarón salino", es un crustáceo sensible a un amplio rango de compuestos químicos, de fácil manejo en el laboratorio, y con un cultivo relativamente sencillo y barato. El objetivo del presente trabajo fue evaluar la toxicidad de agentes antiparasitarios, antimicrobianos e insecticidas sobre A. franciscana para establecer la concentración prevista que no causa efectos (PNEC) sobre los organismos marinos y obtener los niveles guía para la protección de la vida acuática. Con los nauplios II de A. franciscana, dentro de las 24 h de eclosión, se procedió a realizar los bioensayos de toxicidad calculando la Concentración letal media (CL50) a 24 h y 48 h de exposición. Se observó la siguiente secuencia de mayor a menor toxicidad a 48 h de exposición para tres agentes antiparasitarios comerciales: Mebendazol >Albendazol >Metronidazol. Con relación al efecto tóxico letal de seis agentes antimicrobianos comerciales se vio la siguiente secuencia de mayor a menor toxicidad a 48 h de exposición: Triclosan >Clotrimazol >Itraconazol >Ketoconazol >Oxitetraciclina >Mimosa. El camarón salino mostró efectos de mortalidad por acción de cinco sustancias con propiedades insecticidas, encontrándose el siguiente orden de mayor a menor mortalidad a 48 h de exposición: Cipermetrina >Rotenona >Carbaryl >Canela >Malation. Las tres sustancias químicas calificadas como muy tóxicas y que presentaron los niveles guía más bajos para la protección de la vida acuática fueron Triclosan (0,72 ug·L-1), Cipermetrina (0,84 ug·L-1) y Clotrimazol (0,97 ug·L-1). Se observó que diez (71,42%) de las sustancias químicas mostraron fuerte actividad citotóxica (AU)


Artemia franciscana "brine shrimp", is sensitive to a wide range of chemical structures, and easy handling in the laboratory and with a relatively simple and inexpensive crustacean culture. The aim of this study was to evaluate the toxicity of parasiticides agent, antimicrobials agent and insecticides on A. franciscana to establish Predicted No-Effect Concentration (PNEC) on marine organisms and obtain guidance levels for the protection of aquatic life. With A. franciscana nauplii II, within 24 h of hatching, we proceeded to perform toxicity bioassays calculating the average lethal concentration (LC50) at 24 h and 48 h of exposure. The following sequence of high to low toxicity to 48 h of exposure to three commercial antiparasitic agents were observed: Mebendazole> Albendazole> Metronidazole. Regarding the lethal toxic effect of six commercial antimicrobial agents about A. franciscana, the following sequence of toxicity at 48 h of exposure was observed: Triclosan> Clotrimazole> Itraconazole> Ketoconazole> oxytetracycline> Mimosa. The brine shrimp mortality showed effects on five substances with insecticidal properties, meeting the following order from highest to lowest mortality at 48 h of exposure Cipermethrin >Rotenone >Carbaryl >Cinnamon >Malathion. The three chemicals were classified as very toxic and presented lower levels guidance for the protection of aquatic life were Triclosan (0,72 ug·L-1), Cipermetrina (0,84 ug·L-1) y Clotrimazol (0,97 ug·L-1). Ten of chemicals (71.42%) showed strong cytotoxic activity (AU)


Assuntos
Antiparasitários/toxicidade , Inseticidas/toxicidade , Artemia , Crustáceos , Clotrimazol/toxicidade , Anti-Infecciosos/toxicidade , Peptídeos Catiônicos Antimicrobianos/toxicidade , Mortalidade , Mebendazol/toxicidade , Albendazol/toxicidade , Itraconazol/toxicidade , Cetoconazol/toxicidade , Triclosan/toxicidade , Oxitetraciclina/toxicidade , Rotenona/toxicidade , Bioensaio/métodos
6.
Rev. esp. enferm. dig ; 104(4): 165-184, abr. 2012.
Artigo em Espanhol | IBECS | ID: ibc-100190

RESUMO

La insuficiencia hepática crónica produce alteraciones que afectan a la cinética de los medicamentos y a pesar de que su ajuste se basa en el índice Child-Pugh, no se disponen de recomendaciones y/o algoritmos de referencia que faciliten su dosificación. Se realizó una revisión bibliográfica de la dosificación en insuficiencia hepática crónica de los medicamentos de la guía del hospital incluidos en el listado de fármacos que la OMS recomienda no utilizar o utilizar con precaución en pacientes con enfermedad hepática, añadiendo las novedades terapéuticas de los últimos años. Para ello se revisaron las fichas técnicas, base DrugDex- Micromedex, recomendaciones de la OMS y artículos de revisión de los últimos 10 años en Medline; además, se calcularon los parámetros cinéticos de cada fármaco con el objeto de establecer una recomendación teórica basada en la propuesta de Delcò y Huet. Se presentan recomendaciones para 186 medicamentos, según lo indicado en la ficha técnica (49,5%), DrugDex-Micromedex (26,3%) y OMS (18,8%); 6 recomendaciones se realizaron en base a publicaciones específicas y en 4 fármacos se propuso la recomendación teórica basada en los parámetros farmacocinéticos. Las recomendaciones finales para el manejo clínico fueron de: modificación de dosis (26,9%), monitorización hepática/analítica del paciente (8,6%), contraindicación (18,8%), emplear con precaución (19,3%) y no requerir ajuste (26,3%). En esta revisión se presentan recomendaciones específicas para el manejo práctico del paciente con insuficiencia hepática crónica, obtenida mediante una síntesis de la bibliografía publicada y completada con aplicación de una metodología teórica(AU)


Chronic liver diseases (CLD) alter the kinetics of drugs. Despite dosage adjustment is based on Child-Pugh scores, there are no available recommendations and/or algorithms of reference to facilitate dosage regimens. A literature review about dose adjustment of the drugs from the hospital guide -which are included in the list of the WHO recommended drugs to be avoided or used with caution in patients with liver disease- was carried out. The therapeutic novelties from the last few years were also included. In order to do so, the summary of product characteristics (SPC), the database DrugDex- Micromedex, the WHO recommendations and the review articles from the last 10 years in Medline were reviewed. Moreover, the kinetic parameters of each drug were calculated with the aim of establishing a theoretical recommendation based on the proposal of Delcò and Huet. Recommendations for 186 drugs are presented according to the SPC (49.5%), DrugDex-Micromedex (26.3%) and WHO (18.8%) indications; six recommendations were based on specific publications; the theoretical recommendation based on pharmacokinetic parameters was proposed in four drugs. The final recommendations for clinical management were: dosage modification (26.9%), hepatic/analytical monitoring of the patient (8.6%), contraindication (18.8%), use with caution (19.3%) and no adjustment required (26.3%). In this review, specific recommendations for the practical management of patients with chronic liver disease are presented. It has been elaborated through a synthesis of the published bibliography and completed by following a theoretical methodology(AU)


Assuntos
Humanos , Masculino , Feminino , Insuficiência Hepática/complicações , Insuficiência Hepática/tratamento farmacológico , Hepatopatias/tratamento farmacológico , Prescrições de Medicamentos/normas , Relação Dose-Resposta a Droga , Antibióticos Antituberculose/farmacocinética , Antituberculosos/farmacocinética , Busserrelina/farmacocinética , Farmacocinética , Legislação de Medicamentos/normas , Legislação de Medicamentos , Anti-Infecciosos/farmacocinética , Peptídeos Catiônicos Antimicrobianos/farmacocinética , Antirretrovirais/farmacocinética , Leuprolida/farmacocinética
7.
Int. microbiol ; 14(4): 213-223, dic. 2011.
Artigo em Inglês | IBECS | ID: ibc-102986

RESUMO

The presence of the antimicrobial peptide (AMP) biosynthetic genes srfAA (surfactin), bacA (bacylisin), fenD (fengycin), bmyB (bacyllomicin), spaS (subtilin), and ituC (iturin) was examined in 184 isolates of Bacillus spp. obtained from plant environments (aerial, rhizosphere, soil) in the Mediterranean land area of Spain. Most strains had between two and four AMP genes whereas strains with five genes were seldom detected and none of the strains had six genes. The most frequent AMP gene markers were srfAA, bacA, bmyB, and fenD, and the most frequent genotypes srfAA-bacA-bmyB and srfAAbacA- bmyB-fenD. The dominance of these particular genes in Bacillus strains associated with plants reinforces the competitive role of surfactin, bacyllomicin, fengycin, and bacilysin in the fitness of strains in natural environments. The use of these AMP gene markers may assist in the selection of putative biological control agents of plant pathogens (AU)


No disponible


Assuntos
Humanos , Peptídeos Catiônicos Antimicrobianos/genética , Bacillus/genética , Plantas/microbiologia , Controle de Pragas/tendências , Marcadores Genéticos , Espanha
8.
Nutr. hosp ; 25(4): 555-560, jul.-ago. 2010. tab
Artigo em Espanhol | IBECS | ID: ibc-95501

RESUMO

La hepcidina, péptido antimicrobiano, cuya síntesis se encuentra regulada por el estado del hierro e inflamación, juega un importante papel en la homeostasis del hierro en pacientes hemodializados (HD). Es medida a través de la prohepcidina sérica. Objetivo: Determinar los niveles séricos de prohepcidina y su relación con ferritina sérica, proteína C reactiva (PCR) y albúmina en pacientes HD tratados o no con eritropoyetina recombinante (EPO), que asistieron a un Centro de Salud del Estado Carabobo-Venezuela. Metodología: Esta investigación es de tipo descriptiva, correlacional y de campo, cuya muestra estuvo conformada por 71 pacientes HD; 57 de éstos tratados con EPO. Se determinó prohepcidina sérica, ferritina, hemoglobina, hematocrito, PCR y albúmina. Se definió anemia (hemoglobina < 10 g/dL) y deficiencia de hierro (ferritina < 100 ng/mL) de acuerdo al criterio recomendado por grupo K/DOQUI. Valores de referencia: Albúmina 3,5 a 4,8 g/dL, para procesos inflamatorios agudos (PCR > 10 mg/L). Resultados: El promedio para la prohepcidina fue de 397,5 ng/mL. Se observó un alto porcentaje de anemia (87,3%) y un 22,5% de pacientes con ferritina sérica baja. No se observaron diferencias estadísticamente significativas para ferritina, albúmina, PCR y prohepcidina, entre pacientes con y sin tratamiento con EPO. Solo la variable PCR se correlaciona significativamente (rho = 0,276; p =0,020), con prohepcidina. Conclusión: Pacientes HD presentan niveles elevados de prohepcidina, esto pudiera deberse al proceso inflamatorio frecuentemente observado en estos pacientes y no al estado de hierro medido a través de los niveles de ferritina sérica (AU)


Hepcidin, an antimicrobial peptide which synthesis is regulated by iron status and inflammation, plays an important role in iron homeostasis in hemodialysed (HD) patients. It is measured by measuring serum prohepcidin. Objective: To determine serum prohepcidin levels and their relationship with serum ferritin, C reactive protein (CRP), and albumin in HD patients treated or not with recombinant erythropoietin (EPO) that attended the Health Centre of the Carabobo State in Venezuela. Methodology: This is a descriptive, correlational, and field investigation with a sample comprised by 71 HD patients of whom 57 were treated with EPO. Serum prohepcidin, ferritin, haemoglobin, hematocrit, CRP, and albumin were determined. Anaemia (haemoglobin < 10 g/dL) and iron deficiency (ferritin < 100 ng/mL) were defined according to the criteria recommended by the K/DOQUI group. Reference values: Albumin 3.5-4.8 g/dL, and for acute inflammatory conditions (CRP > 10 mg/L.). Results: The mean value for prohepcidin was 397.5 ng/mL. A high percentage of anaemia was observed (87.3%) and 22.5% of the patients had low levels of serum ferritin. There were no statistically significant differences for ferritin, albumin, CRP, or prohepcidin, between patients with and without EPO therapy. Only the CRP value was significantly correlated (rho = 0.276; p = 0.020) with prohepcidin. Conclusion: HD patients present high levels of prohepcidin, and this may be due to the common ongoing inflammatory process in these patients and not to the iron status measured through serum ferritin levels (AU)


Assuntos
Humanos , Diálise Renal/efeitos adversos , Peptídeos Catiônicos Antimicrobianos/sangue , 16595/sangue , Eritropoetina/uso terapêutico , Ferritinas/sangue , Receptores de Peptídeos/análise , Ferro da Dieta/metabolismo , Inflamação/fisiopatologia
9.
An. sist. sanit. Navar ; 31(supl.1): 99-113, 2008. ilus, tab
Artigo em Es | IBECS | ID: ibc-65106

RESUMO

Las infecciones del sistema nervioso central son enfermedades frecuentes en la atención urgente, pudiendo ser de origen bacteriano, parasitario o vírico. Los síntomas iniciales pueden ser inespecíficos, lo que puede dificultar y retrasar su diagnóstico, por lo que es de suma importancia toda la información que pueda obtenerse a través de la anamnesis y exploración física y con frecuencia exploraciones complementarias. En los últimos cien años, con la introducción de fármacos antibióticos ha disminuido de forma importante la mortalidad secundaria a meningoencefalitis, pero a pesar de ello siguen provocando alta morbi-mortalidad. Otros fenómenos, como las campañas de vacunación, movimientos migratorios, infección por el virus de la inmunodeficiencia humana y otros estados de inmunosupresión, han dado lugar a importantes cambios epidemiológicos como son la práctica desaparición de algunas infecciones o la aparición de otras previamente casi inexistentes. La lista de infecciones potenciales de sistema nervioso central es extensa por lo que en este artículo de revisión expondremos desde el punto de vista clínico, diagnóstico y terapéutico las más frecuentes en nuestro medio y algunas que, aunque poco frecuentes, pueden requerir atención urgente por su gravedad (AU)


Infections of the central nervous system are frequent diseases in emergency care. They can have a bacterial, parasitic or viral origin. Initial symptoms can be non-specific, which can complicate and delay diagnosis, hence the extreme importance of all the information that can be obtained through anamnesis and physical exploration, with frequent complementary explorations. In the last hundred years, with the introduction of antibiotic drugs, there has been a significant fall in mortality secondary to meningoencephalitis, but in spite of that they continue to provoke high morbidity and mortality. Other phenomena, such as vaccination campaigns, migratory movements, infection by HIV and other states of immunosuppression, have given rise to important epidemiological changes such as the virtual disappearance of some infections or the appearance of others that rarely existed previously. The list of potential infections of the central nervous system is extensive, which is why in this review we set out, from the clinical, diagnostic and therapeutic point of view, those that are most frequent in our environment and some that, although very infrequent, might require emergency attention due to their severity (AU)


Assuntos
Humanos , Masculino , Feminino , Sistema Nervoso Central/fisiopatologia , Emergências/epidemiologia , Meningoencefalite/diagnóstico , Meningoencefalite/terapia , Abscesso Encefálico/diagnóstico , Abscesso Encefálico/terapia , Infecções Oportunistas/diagnóstico , Infecções Oportunistas/terapia , Empiema/complicações , Tétano/complicações , Anamnese/métodos , Meningoencefalite/complicações , Sistema Nervoso Central/patologia , Abscesso/complicações , Peptídeos Catiônicos Antimicrobianos/uso terapêutico , Corticosteroides/uso terapêutico , Tuberculina/uso terapêutico , Rifampina/uso terapêutico , Etambutol/uso terapêutico , Estreptomicina/uso terapêutico
11.
Arch. Soc. Esp. Oftalmol ; 82(5): 299-300, mayo 2007. ilus
Artigo em Es | IBECS | ID: ibc-054976

RESUMO

Caso clínico: Se describe el caso de una mujer de 74 años que tuvo alucinaciones visuales después de la administración de ciprofloxacino cuando estaba tomando una teofilina, resolviéndose el cuadro alucinatorio cuando se suspendió el ciprofloxacino. Discusión: Aunque es poco frecuente, todos los oftalmólogos deberían estar alerta y conocer los posibles efectos adversos visuales en pacientes con tratamiento simultáneo de quinolonas y teofilinas


Case report: We describe a case of a 74-year-old woman who experienced visual hallucinations after ciprofloxacin administration, when she was also taking theophylline, which resolved on cessation of the ciprofloxacin. Discussion: Although uncommon, all ophthalmologists should be aware of this potential problem and be familiar with the adverse visual effects which may occur in patients simultaneously administered quinolones and theophylline


Assuntos
Feminino , Pessoa de Meia-Idade , Humanos , Ciprofloxacina/efeitos adversos , Ciprofloxacina/uso terapêutico , Alucinações/complicações , Alucinações/diagnóstico , Teofilina/uso terapêutico , Quinolonas/uso terapêutico , Tomografia Computadorizada de Emissão/métodos , Peptídeos Catiônicos Antimicrobianos/efeitos adversos , Peptídeos Catiônicos Antimicrobianos/uso terapêutico , Quinolonas/administração & dosagem , Quinolonas/efeitos adversos
13.
Rev. esp. quimioter ; 14(2): 184-190, jun. 2001.
Artigo em Es | IBECS | ID: ibc-14390

RESUMO

El objetivo de este estudio fue determinar la actividad in vitro de CA(1-8)M(1-18), un péptido sintético híbrido cecropina A-melitina, frente a aislamientos clínicos multirresistentes de Acinetobacter baumannii. Se estudió la CMI en 20 aislamientos clínicos de A. baumannii con diferente perfil de resistencia, mediante microdilución en caldo, obteniéndose CMI50 = 4 mg/l, CMI90 = 4 mg/l e intervalo de 2 a 8 mg/l. En la cepa control se ensayó el efecto de diferentes factores, como el material de la placa de microdilución (poliestireno o polipropileno), el suplemento (5 por ciento o 10 por ciento de suero fetal bovino o 5 por ciento de sangre de caballo), el tamaño del inóculo (105, 106, 107 y 108 UFC/ml) y el periodo de incubación (24 o 48 h). La CMI fue similar en los dos tipos de placas de microdilución utilizadas e independiente del suplemento con suero fetal bovino o sangre de caballo; sin embargo, se observó un aumento del valor al utilizar un inóculo elevado o incubación prolongada. La actividad se determinó mediante curvas de muerte a diluciones dobles seriadas del péptido de 45,7 mg/l a 2,8 mg/l (16 a 1 mM) de CA(1-8)M(1-18) en la cepa control y en una cepa multirresistente, con un inóculo inicial de 105-106 UFC/ml y de 109-1010 UFC/ml. Se observó muerte completa de todos los microorganismos a una concentración de 45,7 mg/l. CA(1-8)M(1-18) mostró buena actividad in vitro frente a los aislamientos de A. baumannii probados independientemente del patrón de resistencia a los antimicrobianos clásicos, y podría ser un futuro candidato para tratar infecciones por A. baumannii multirresistente, aunque serán necesarios estudios farmacológicos y de toxicidad (AU)


Assuntos
Humanos , Resistência a Múltiplos Medicamentos , Meliteno , Fragmentos de Peptídeos , Peptídeos Catiônicos Antimicrobianos , Antibacterianos , Resistência a Medicamentos , Acinetobacter , Infecções por Acinetobacter , Testes de Sensibilidade Microbiana
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...